Clavix vs Morningstar
Morningstar is one of the most respected names in long-horizon research: analyst reports, star ratings, and fair-value estimates built for patient, buy-and-hold investing and fund selection. Clavix works on a shorter clock. It turns each stock into one A+ to F risk grade, refreshes it every trading day, and writes you a plain-English brief before the open. Morningstar helps you decide what to own for years; Clavix helps you watch the risk of what you own, day to day.
Side by side
| Clavix | Morningstar | |
|---|---|---|
| Core job | Daily risk grade + morning brief | Long-term research and fund analysis |
| Main output | One A+ to F grade per stock and portfolio | Star ratings, fair-value estimates, reports |
| Time horizon | Today: what changed overnight | Years: long-term value |
| Coverage focus | 550+ US stocks and major ETFs | Broad stocks and deep fund/ETF research |
| Risk view | Five dimensions: financial, news, macro, sector, price | Valuation, moat, and uncertainty framing |
| Brokerage link | None; manual entry by design | Offers portfolio tools |
| Best for | A daily risk pulse on your holdings | Long-term buy-and-hold and fund picks |
When Morningstar is the better fit
If you invest for the long run, lean on funds and ETFs, and want rigorous independent analysis of what a business is worth, Morningstar is built for that. Its star ratings and fair-value work are a trusted anchor for patient investors and retirement portfolios.
When Clavix is the better fit
If you actively hold individual stocks and want a quick daily answer to "did my risk change overnight?", Clavix is built for that. It grades your portfolio A+ to F, breaks each grade into five dimensions, and writes a short brief before the open, no valuation model to read. Try it with the free web grader first.
Can you use both?
They fit different jobs, so many investors run both. Use Morningstar to decide what deserves a place in the portfolio for the long term, and Clavix to keep a daily eye on the risk of what is already in it. Long-horizon research and a daily risk monitor are not the same tool.